A Phase 1/2 interventional study of Henggliflozin Combined with Probiotics and Henggliflozin in Heart Failure, Preserved Ejection Fraction, sponsored by The First Affiliated Hospital of Air Force Medicial University. Not yet recruiting at 1 site in China. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-07-07.
Sponsored by The First Affiliated Hospital of Air Force Medicial University · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
HFpEF has a high incidence and lacks effective therapy, and its onset is closely related to systemic inflammation and intestinal dysbacteriosis.SGLT-2i exerts its effects by diuresis, anti-inflammatory and improving energy metabolism, whereas probiotics modulate intestinal flora, reduce inflammatory markers, and regulate immune responses.The combination of the two drugs is not only expected to exert synergistic therapeutic potential, but may also reduce the risk of sarcopenia associated with SGLT-2i weight loss.This study aims to combine henagliflozin and a probiotic preparation on the basis of standard anti-heart-failure therapy, and to observe their effects on cardiac and renal function, intestinal barrier function, quality of life, and exercise tolerance in elderly patients with HFpEF, while exploring the underlying mechanisms, so as to provide new data and therapeutic strategies for the treatment of elderly HFpEF patients.
199 studies on the registry are indexed under Heart Failure, Diastolic; 44 are open to participants now.
This study's planned enrollment of 162 is above the median of 48 across 139 interventional studies indexed under Heart Failure, Diastolic.
Browse Heart Failure, Diastolic studies →The First Affiliated Hospital of Air Force Medicial University is the lead sponsor of 6 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1. Age over 60 years; 2.Relevant investigations within 6 months meet diagnostic criteria for HFpEF:
Exclusion Criteria:
1. the patient's symptoms are due to noncardiac disease; 2. In those with to Henggliflozin:
<!-- -->
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Henggliflozin Combined with Probiotics
Drug: Henggliflozin
Drug: double placebo
Primary anti-HF therapy + Henagliflozin Proline Tablets (10mg, 1 times/day) + clostridial enterococcus triple live tablet (400mg, 3 times/day) orally, for 12 weeks.
Primary anti-HF therapy + Henagliflozin Proline Tablets (10mg, 1 times/day) + placebo (400mg, 3 times/day) orally, for 12 weeks.
Primary anti-HF therapy +Two types of placebo tablets orally, for 12 weeks.
Kansas City Cardiomyopathy Questionnaire (KCCQ)scale score
The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a validated patient-reported outcome measure used to assess heart failure-specific quality of life. The change in the overall summary score from baseline to Week 12 will be compared between the groups. Higher scores indicate better health status.
Time frame: Baseline, Week 4, Week 8,Week 12
NYHA functional classification
The New York Heart Association (NYHA) functional classification is used to assess the severity of heart failure symptoms. Changes in NYHA class from baseline to Week 12 will be compared between groups.
Time frame: Baseline, Week 4, Week 8,Week 12
6-Minute Walk Test (6MWT) Distance
The 6-minute walk test is a measure of functional capacity in patients with heart failure. The distance walked in 6 minutes will be assessed at baseline, Week 4, Week 8,and Week 12 to evaluate changes in exercise tolerance.
Time frame: Baseline, Week 4, Week 8, Week 12
Serum N-terminal pro-B-type Natriuretic Peptide (NT-proBNP) Level
Serum NT-proBNP is a key biomarker for heart failure severity. Levels will be measured at baseline, Week 4, Week 8, and Week 12 to assess changes in cardiac strain.
Time frame: Baseline, Week 4, Week 8,Week 12
Minnesota Living with Heart Failure Questionnaire (MLHFQ) Total Score
The MLHFQ is a patient-reported questionnaire evaluating the impact of heart failure on quality of life. Higher scores indicate greater impairment. Changes from baseline to Week 12 will be compared.
Time frame: Baseline, Week 4, Week 8,Week 12
Serum Inflammatory Biomarkers (NLRP3, IL-1β, TNF-α, IL-6, MCP-1, ICAM-1, VCAM-1)
Serum levels of the following inflammatory and endothelial activation markers will be measured to assess the effect of drugs on systemic inflammation in patients with HFpEF: NLRP3, IL-1β, TNF-α, IL-6, MCP-1, ICAM-1, and VCAM-1. Each biomarker will be analyzed separately for changes from baseline.
Time frame: Baseline, Week 4, Week 8, Week 12
Gut Microbiota Composition and Diversity
Fecal samples will be collected for 16S rRNA sequencing to analyze changes in gut microbiota composition, diversity, and taxonomic profiles following drugs intervention.
Time frame: Baseline, Week 4, Week 8, Week 12
Frailty Status Using the Fried Frailty Phenotype Criteria
Frailty status will be assessed using the Fried criteria to evaluate changes in physical vulnerability.
Time frame: Baseline, Week 4, Week 8, Week 12
Nutritional Status Using the Mini Nutritional Assessment (MNA) Scale
Nutritional status will be evaluated using the Mini Nutritional Assessment (MNA) scale. Changes in total score from baseline to Week 12 will be compared.
Time frame: Baseline, Week 4, Week 8, Week 12
Basic Activities of Daily Living (BADL) Scale Score
The BADL scale will be used to assess changes in patients' functional independence in daily activities.
Time frame: Baseline, Week 4, Week 8, Week 12
SARC-F Scale Score
The SARC-F questionnaire is a validated tool for sarcopenia screening, assessing strength, assistance with walking, rising from a chair, climbing stairs, and falls. Changes in total score from baseline to Week 12 will be evaluated.
Time frame: Baseline, Week 4, Week 8, Week 12
Fecal Short Chain Fatty Acids (SCFAs)
Concentrations of fecal short-chain fatty acids, including acetate, propionate, and butyrate, will be quantified to assess changes in gut microbial fermentation.
Time frame: Baseline, Week 12
Serum Trimethylamine-N Oxide (TMAO)
Serum TMAO levels will be measured as a marker of gut microbiota-dependent metabolism of dietary phosphatidylcholine and carnitine.
Time frame: Baseline, Week 12
Serum Bile Acids Profile
Concentrations of primary and secondary bile acids, such as cholic acid and deoxycholic acid, will be quantified to evaluate changes in bile acid metabolism.
Time frame: Baseline, Week 12
White Blood Cell (WBC) Count
WBC count will be measured to monitor changes in systemic inflammatory/immune status.
Time frame: Baseline, Week 12
Hemoglobin (HGB) Concentration
Hemoglobin concentration will be measured to assess changes in oxygen-carrying capacity.
Time frame: Baseline, Week 12
Platelet (PLT) Count
Platelet count will be measured to evaluate changes in hemostatic/thrombotic potential.
Time frame: Baseline, Week 12
Serum Creatinine
Serum creatinine level will be measured to assess renal function.
Time frame: Baseline, Week 12
Estimated Glomerular Filtration Rate (eGFR)
eGFR will be calculated as a marker of renal function.
Time frame: Baseline, Week 12
Alanine Aminotransferase (ALT)
Serum ALT level will be measured to assess hepatocellular integrity.
Time frame: Baseline, Week 12
Aspartate Aminotransferase (AST)
Serum AST level will be measured to assess hepatocellular integrity.
Time frame: Baseline, Week 12
Fasting Blood Glucose
Fasting blood glucose concentration will be measured to assess glycemic status.
Time frame: Baseline, Week 12
Serum Electrolytes (Sodium, Potassium, Chloride)
Serum concentrations of sodium, potassium, and chloride will be measured. Each electrolyte will be analyzed separately for changes from baseline.
Time frame: Baseline, Week 12
Left Atrial Volume Index (LAVI)
LAVI will be measured to assess changes in left atrial remodeling.
Time frame: Baseline, Week 12
Left Ventricular Mass Index (LVMI)
LVMI will be measured to assess changes in left ventricular hypertrophy.
Time frame: Baseline, Week 12
Pulmonary Artery Systolic Pressure (PASP)
PASP will be measured to assess changes in pulmonary artery pressure.
Time frame: Baseline, Week 12
E/e' Ratio
The E/e' ratio will be measured to assess changes in left ventricular filling pressure.
Time frame: Baseline, Week 12
Total Body Fat Mass
Body fat mass will be measured to assess changes in adiposity.
Time frame: Baseline, Week 12
PDFs hosted by the registry, ClinicalTrials.gov.
Start is estimated for Jul 2026; primary completion for Sep 2027, 14 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Henagliflozin
The First Affiliated Hospital of Air Force Medicial University